Drugs / SI-722
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04208087 | Mar 2020 → Jan 2021 | interstitial cystitis | Seikagaku Corporation | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-11-08 | Seikagaku Corporation | Seikagaku Initiates a Phase I/II Clinical Study for SI-722 in the U.S., an Indication for Interstitial Cystitis and Bladder Pain Syndrome seikagaku.co.jp ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SI-722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04208087 ↗ |